We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.49B
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
-1.62%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$2.99B
AUM Growth
-$546M
Cap. Flow
-$71.8M
Cap. Flow %
-2.4%
Top 10 Hldgs %
48.59%
Holding
90
New
10
Increased
29
Reduced
22
Closed
16

Top Buys

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$131M
2
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
+$75.7M
3
IGMS
IGM Biosciences
IGMS
+$63.5M
4
ALLK
Allakos
ALLK
+$51.3M
5
NVRO
NEVRO CORP.
NVRO
+$48.5M

Top Sells

Rank Stock Value
1
ARRY
Array Biopharma Inc
ARRY
+$405M
2
EHTH icon
eHealth
EHTH
+$76.5M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$62.6M
4
ELV icon
Elevance Health
ELV
+$51.8M
5
UNH icon
UnitedHealth
UNH
+$34M

Sector Composition

Rank Sector Weight
1 Healthcare 99.06%
2 Miscellaneous 0.93%
3 Energy 0.01%
4 Technology 0%
5 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALLK
1
DELISTED
Allakos
ALLK
$242M 8.1%
3,077,128
+776,827
+34% +$51.3M
FOLD
2
DELISTED
Amicus Therapeutics
FOLD
$183M 6.12%
22,790,134
-2,500
-0% -$27.1K
FATE icon
3
Fate Therapeutics
FATE
$291M
$174M 5.83%
11,216,809
+857,143
+8% +$16.4M
DCPH
4
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$162M 5.43%
4,780,898
+2,557,522
+115% +$75.7M
ALDR
5
DELISTED
Alder Biopharmaceuticals
ALDR
$155M 5.2%
8,244,896
– –
ARGX icon
6
argenx
ARGX
$64B
$123M 4.12%
1,080,432
+11,600
+1% +$1.57M
BMY icon
7
Bristol-Myers Squibb
BMY
$136B
$114M 3.82%
2,252,600
+583,200
+35% +$27.4M
ALXN
8
DELISTED
Alexion Pharmaceuticals
ALXN
$114M 3.81%
+1,162,200
New +$131M
QURE icon
9
uniQure
QURE
$3.38B
$94.9M 3.17%
2,410,125
+740,600
+44% +$42.7M
EPZM
10
DELISTED
Epizyme, Inc
EPZM
$89.1M 2.98%
8,636,933
-92,209
-1% -$1.16M
RGNX icon
11
Regenxbio
RGNX
$638M
$84.1M 2.81%
2,362,486
+971,110
+70% +$39.3M
BOLD
12
DELISTED
Audentes Therapeutics, Inc
BOLD
$83.2M 2.79%
2,962,655
-9,512
-0.3% -$325K
TNDM icon
13
Tandem Diabetes Care
TNDM
$1.49B
$68.4M 2.29%
1,160,401
-5,631
-0.5% -$359K
WVE icon
14
Wave Life Sciences
WVE
$993M
$65.2M 2.18%
3,177,760
+458,053
+17% +$10.5M
TCDA
15
DELISTED
Tricida, Inc. Common Stock
TCDA
$64.1M 2.15%
2,077,700
+132,500
+7% +$4.44M
ATRA icon
16
Atara Biotherapeutics
ATRA
$92.3M
$63.8M 2.14%
180,789
-3,248
-2% -$1.21M
CELG
17
DELISTED
Celgene Corp
CELG
$55.9M 1.87%
562,700
+5,700
+1% +$542K
IGMS
18
DELISTED
IGM Biosciences
IGMS
$55.8M 1.87%
+3,144,000
New +$63.5M
NVRO
19
DELISTED
NEVRO CORP.
NVRO
$55.4M 1.85%
643,864
+640,464
+18,837% +$48.5M
WMGI
20
DELISTED
Wright Medical Group Inc
WMGI
$49.6M 1.66%
2,404,157
+32,000
+1% +$762K
DXCM icon
21
DexCom
DXCM
$34.3B
$45.4M 1.52%
1,216,632
+528,232
+77% +$20.5M
SYRS
22
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$40.4M 1.35%
388,875
+26,837
+7% +$2.53M
PEN icon
23
Penumbra
PEN
$12.7B
$40.1M 1.34%
+297,972
New +$46.1M
PRAH
24
DELISTED
PRA Health Sciences, Inc.
PRAH
$39.2M 1.31%
+395,400
New +$39.3M
KRYS icon
25
Krystal Biotech
KRYS
$10.4B
$37.4M 1.25%
1,078,300
-2,000
-0.2% -$89.4K
1
2 3 4

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q3 2019 Portfolio in Review

As of Q3 2019, Redmile Group held 90 positions worth $2.99B, down 15% from $3.53B the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Redmile Group's Q3 2019 filing shows 10 new, 29 increased, 22 reduced and 16 closed positions. Its largest new stake was Alexion Pharmaceuticals: 1,162,200 shares worth $114M. The largest sale was Array Biopharma Inc, an estimated $405M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 96% a quarter earlier, followed by Miscellaneous and Energy.

  • Redmile Group's largest Q3 2019 buy was Alexion Pharmaceuticals: 1,162,200 shares worth $114M.
  • Redmile Group added most to Deciphera Pharmaceuticals, Inc. Common Stock in Q3 2019, an estimated $75.7M increase.
  • Redmile Group's biggest Q3 2019 reduction was UnitedHealth, cutting an estimated $34M.
  • Redmile Group fully exited Array Biopharma Inc in Q3 2019, selling an estimated $405M.
  • Redmile Group's ten largest holdings make up 49% of its $2.99B portfolio in Q3 2019.
  • Redmile Group opened 10 new positions and closed 16 in Q3 2019.
  • Redmile Group's portfolio value fell 15% quarter-over-quarter to $2.99B.

Based on Redmile Group's 13F filing for Q3 2019, filed 14 Nov 2019.